Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, today announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
NASH is a chronic metabolic liver disease that affects more than 115 million people worldwide1. The condition is caused by build-up of fat and inflammation in the liver. This causes progressive damage to the liver and can lead to end-stage liver disease and death.
NASH is a ‘silent’ disease due to lack of symptoms in the early stages and, as a result, it is estimated that nine out of 10 people living with NASH go undiagnosed2. To significantly increase early diagnosis, broadly accepted non-invasive tests for diagnosing people living with NASH are needed, as confirmatory diagnosis currently relies on an invasive procedure known as a liver biopsy.
Echosens and Novo Nordisk will collaborate to support additional clinical validation, generation of real-world evidence and adoption of non-invasive diagnostic tests for NASH and work together to increase awareness of the disease and the importance of early diagnosis and management. The companies have a shared ambition of doubling diagnostic rates for people living with advanced to severe NASH by 2025.
“NASH is the more severe form of non-alcoholic fatty liver disease (NAFLD). It has few non-specific or no symptoms in its early stage, leading to inappropriate referrals to secondary care and patients often remaining undiagnosed until irreversible complications occur,” said Dominique Legros, CEO at Echosens. “There is a pressing need for a broader adoption of our non-invasive liver tests to improve the diagnosis of people living with NASH, and we are proud to partner with Novo Nordisk to combine our strengths and shared mission to empower medical professionals with improved ways to assess, diagnose and manage the condition.”
NASH is more common in people living with obesity (82% of people with NASH are living with obesity) and conditions related to obesity, such as type 2 diabetes (44% of people with NASH are living with type 2 diabetes)3. The low diagnosis rate for NASH is partly caused by a lack of awareness of the condition and associated risk factors among at-risk patients, healthcare providers, payers and policymakers.
“At Novo Nordisk we are committed to driving change in NASH, to develop new treatment options and advance care for this serious, chronic disease. An important step towards realizing that ambition is to ensure that we can identify the people in need of care,” said Camilla Sylvest, executive vice president for Commercial Strategy & Corporate Affairs at Novo Nordisk. “But we cannot solve this challenge alone and through our partnership with Echosens, we hope to leverage our complementary skills to meet the needs of patients, healthcare providers and other stakeholders striving to address this ‘silent’ epidemic.”
Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD). It is a progressive metabolic liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, and eventually end-stage liver disease and death. The risk of progression to advanced liver disease, including liver cancer, is higher in people with NASH than in the general population, and NASH is predicted to be the leading cause of liver transplantation by 2030. Moreover, NASH increases the risk of developing cardiovascular disease. Currently, no treatment is globally approved for the treatment of NASH, and people with NASH are left with very few management options.
By Novo Nordisk, Press Release
The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.
Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.